About 布加替尼 API

作用机制

Brigatinib is a type of cancer drug known as an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the activity of ALK, a protein that is often over-expressed in certain types of cancer cells, such as non-small cell lung cancer (NSCLC).

The over-expression of ALK leads to uncontrolled cell growth and division, which is a hallmark of cancer. Brigatinib interferes with the activity of ALK by binding to the ALK protein and preventing it from interacting with other proteins that are essential for cell survival and proliferation.

By inhibiting the activity of ALK, brigatinib can help to slow the growth and spread of cancer cells. This can lead to a reduction in the size of tumors and an improvement in overall cancer symptoms.

It is important to note that the mechanism of action of brigatinib may vary depending on the type and stage of cancer being treated. The use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition.

适应症

Brigatinib is a medication that is used to treat a type of cancer known as non-small cell lung cancer (NSCLC). Specifically, it is indicated for the treatment of patients with ALK (anaplastic lymphoma kinase) positive NSCLC who have progressed on or are intolerant to crizotinib.

ALK positive NSCLC is a subtype of NSCLC that is characterized by a genetic alteration in the ALK gene. This alteration leads to the over-expression of ALK, which drives the growth and spread of cancer cells.

Brigatinib works by inhibiting the activity of ALK, which helps to slow the growth and spread of cancer cells. By doing so, it can help to reduce the size of tumors and improve overall cancer symptoms.

It is important to note that the use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition. The drug should only be used in patients with ALK positive NSCLC, as its safety and efficacy have not been established in other types of cancer.

Dr. Reddy's的专长

Dr. Reddy's总部位于印度海得拉巴，是全球领先的活性药物成分（API）供应商之一。 Dr. Reddy's的API业务是美国、欧洲、巴西、拉丁美洲、日本、中国、韩国和新兴市场的制药公司的首选合作伙伴。

Dr. Reddy's博士的API业务在过去30多年来在开发和制造复杂API（如类固醇，多肽，复杂长链分子和高效API（HPAPI /肿瘤药物））方面所建立的深厚技术优势中茁壮成长。 我们在知识产权和法规事务方面的实力可以帮助我们始终如一地达到并超越监管标准，从而为这一专业知识提供补充。 Dr. Reddy's博士 布加替尼 API是研发，知识产权和监管方面广泛专业知识的结果。

帮助我们的客户率先进入市场的关键组成部分是响应式供应链。 我们通过确保所有设施都高效运行并达到最新的质量，安全和生产率标准来实现这一目标。 业务和工厂之间的强大互联可以快速响应动态的市场变化，从而避免短缺并满足需求的突然激增。